Log in

TSE:ONC - Oncolytics Biotech Stock Price, Forecast & News

C$4.05
-0.10 (-2.41 %)
(As of 01/19/2020 11:15 AM ET)
Today's Range
C$4.00
Now: C$4.05
C$4.39
50-Day Range
C$1.41
MA: C$3.09
C$6.15
52-Week Range
C$0.48
Now: C$4.05
C$7.84
Volume220,200 shs
Average Volume789,747 shs
Market CapitalizationC$106.75 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses. It has a research collaboration with Keck School of Medicine of University of Southern California using pelareorep in combination with Keytruda, Velcade, and dexamethasone to treat multiple myeloma; and a clinical collaboration with SOLTI breast cancer research. Oncolytics Biotech Inc. was founded in 1998 and is headquartered in Calgary, Canada.

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+1-403-6707380

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Cash FlowC$0.42 per share
Book ValueC$0.14 per share

Profitability

Miscellaneous

EmployeesN/A
Market CapC$106.75 million
Next Earnings Date3/13/2020 (Estimated)
OptionableNot Optionable

Receive ONC News and Ratings via Email

Sign-up to receive the latest news and ratings for ONC and its competitors with MarketBeat's FREE daily newsletter.


(Ad)


Want to know which stocks should be on your radar this week? Every Sunday we send out the 3 Stock Trades that we predict will be big winners for the week ahead.

Oncolytics Biotech (TSE:ONC) Frequently Asked Questions

What is Oncolytics Biotech's stock symbol?

Oncolytics Biotech trades on the Toronto Stock Exchange (TSX) under the ticker symbol "ONC."

How were Oncolytics Biotech's earnings last quarter?

Oncolytics Biotech, Inc. (TSE:ONC) issued its earnings results on Tuesday, November, 12th. The company reported ($0.16) EPS for the quarter, beating analysts' consensus estimates of ($0.25) by $0.09. View Oncolytics Biotech's Earnings History.

When is Oncolytics Biotech's next earnings date?

Oncolytics Biotech is scheduled to release their next quarterly earnings announcement on Friday, March 13th 2020. View Earnings Estimates for Oncolytics Biotech.

What price target have analysts set for ONC?

2 brokerages have issued 12-month price objectives for Oncolytics Biotech's shares. Their forecasts range from C$9.00 to C$9.00. On average, they expect Oncolytics Biotech's share price to reach C$9.00 in the next twelve months. This suggests a possible upside of 122.2% from the stock's current price. View Analyst Price Targets for Oncolytics Biotech.

What is the consensus analysts' recommendation for Oncolytics Biotech?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oncolytics Biotech in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oncolytics Biotech.

Has Oncolytics Biotech been receiving favorable news coverage?

Media coverage about ONC stock has trended positive recently, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Oncolytics Biotech earned a media sentiment score of 2.2 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View News Stories for Oncolytics Biotech.

Who are some of Oncolytics Biotech's key competitors?

What other stocks do shareholders of Oncolytics Biotech own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oncolytics Biotech investors own include Oncolytics Biotech (ONCY), Oncolytics Biotech (ONCYF), Resverlogix (RVX), Encana (ECA), ProMetic Life Sciences (PLI), Bombardier (BDRBF), Husky Energy (HUSKF), Birchcliff Energy (BIR), First Majestic Silver (FR) and Premier Gold Mines (PG).

Who are Oncolytics Biotech's key executives?

Oncolytics Biotech's management team includes the folowing people:
  • Dr. Matthew C. Coffey, Pres, CEO & Director
  • Mr. Kirk J. Look, Chief Financial Officer
  • Mr. Andrew R. de Guttadauro, Global Head of Bus. Devel. & Pres of Oncolytics Biotech (U.S.) Inc (Age 52)
  • Mr. Michael Moore, VP of Investor Relations & Corp. Communications
  • Dr. Rita Laeufle, Chief Medical Officer

How do I buy shares of Oncolytics Biotech?

Shares of ONC and other Canadian stocks can be purchased through online brokerage accounts that support trading on the Toronto Stock Exchange (TSX). Brokers that permit trading on the TSX include Fidelity, Interactive Brokers, PennTrade and Charles Schwab.

What is Oncolytics Biotech's stock price today?

One share of ONC stock can currently be purchased for approximately C$4.05.

How big of a company is Oncolytics Biotech?

Oncolytics Biotech has a market capitalization of C$106.75 million. View Additional Information About Oncolytics Biotech.

What is Oncolytics Biotech's official website?

The official website for Oncolytics Biotech is http://www.oncolyticsbiotech.com/.

How can I contact Oncolytics Biotech?

Oncolytics Biotech's mailing address is 1167 Kensington Cres Nw Suite 210 Calgary Alberta Canada T2n 1X7, CALGARY, AB 00000, Canada. The company can be reached via phone at +1-403-6707380.


MarketBeat Community Rating for Oncolytics Biotech (TSE ONC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  173 (Vote Outperform)
Underperform Votes:  125 (Vote Underperform)
Total Votes:  298
MarketBeat's community ratings are surveys of what our community members think about Oncolytics Biotech and other stocks. Vote "Outperform" if you believe ONC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ONC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel